Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV-104
- Development stage
- Preclinical
- Lead developer
- Kangweizhonghe
01
Overview
SV-104 is an investigational drug candidate currently in the preclinical stage of development by Kangweizhonghe (Zhongshan) Biopharmaceutical Co., Ltd. It is being developed for the treatment or prevention of brucellosis, a zoonotic infection caused by bacteria of the genus *Brucella*. While specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed, the developer's focus on recombinant protein technology and infectious disease products (such as their Phase 3 tuberculosis diagnostic/vaccine D-EC) suggests that SV-104 may be a recombinant protein or vaccine candidate.
Beyond the preview
Go deeper on SV-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV-104.